JP7637150B2 - 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 - Google Patents
神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 Download PDFInfo
- Publication number
- JP7637150B2 JP7637150B2 JP2022559518A JP2022559518A JP7637150B2 JP 7637150 B2 JP7637150 B2 JP 7637150B2 JP 2022559518 A JP2022559518 A JP 2022559518A JP 2022559518 A JP2022559518 A JP 2022559518A JP 7637150 B2 JP7637150 B2 JP 7637150B2
- Authority
- JP
- Japan
- Prior art keywords
- dextromethorphan
- bupropion
- human
- week
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024212992A JP7890382B2 (ja) | 2020-03-30 | 2024-12-06 | アルツハイマー病に関連する焦燥を治療するための医薬 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002132P | 2020-03-30 | 2020-03-30 | |
| US63/002,132 | 2020-03-30 | ||
| US202063016178P | 2020-04-27 | 2020-04-27 | |
| US63/016,178 | 2020-04-27 | ||
| US202063032517P | 2020-05-29 | 2020-05-29 | |
| US63/032,517 | 2020-05-29 | ||
| US202063032567P | 2020-05-30 | 2020-05-30 | |
| US63/032,567 | 2020-05-30 | ||
| US16/894,713 US10898453B2 (en) | 2013-11-05 | 2020-06-05 | Bupropion as a modulator of drug activity |
| US16/894,713 | 2020-06-05 | ||
| PCT/US2021/024718 WO2021202419A1 (en) | 2020-03-30 | 2021-03-29 | Use of bupropion and dextromethorphan combinations for treating neurological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212992A Division JP7890382B2 (ja) | 2020-03-30 | 2024-12-06 | アルツハイマー病に関連する焦燥を治療するための医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023519965A JP2023519965A (ja) | 2023-05-15 |
| JP2023519965A5 JP2023519965A5 (cg-RX-API-DMAC7.html) | 2023-07-20 |
| JP7637150B2 true JP7637150B2 (ja) | 2025-02-27 |
Family
ID=77930161
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559518A Active JP7637150B2 (ja) | 2020-03-30 | 2021-03-29 | 神経疾患を治療するためのブプロピオンおよびデキストロメトルファンの組み合わせの使用 |
| JP2024212992A Active JP7890382B2 (ja) | 2020-03-30 | 2024-12-06 | アルツハイマー病に関連する焦燥を治療するための医薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024212992A Active JP7890382B2 (ja) | 2020-03-30 | 2024-12-06 | アルツハイマー病に関連する焦燥を治療するための医薬 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4125837A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7637150B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220161414A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115697314A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179048A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202419A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12194006B2 (en) | 2013-11-05 | 2025-01-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12109178B2 (en) | 2013-11-05 | 2024-10-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12569479B2 (en) | 2016-05-25 | 2026-03-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US12472156B2 (en) | 2020-06-05 | 2025-11-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US12433884B2 (en) | 2020-06-05 | 2025-10-07 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| CN122440635A (zh) | 2020-12-01 | 2026-07-24 | 安泰赛普生物风投二代有限责任公司 | 用于降低抑郁症患者的自杀风险的安非他酮和右美沙芬 |
| CA3227072A1 (en) * | 2021-07-21 | 2023-01-26 | Antecip Bioventures Ii Llc | Treatment of depression |
| JP2025517368A (ja) * | 2022-05-17 | 2025-06-05 | アンテシップ バイオベンチャーズ トゥー エルエルシー | うつ病の治療 |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| US12194036B2 (en) | 2022-07-07 | 2025-01-14 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| US11844797B1 (en) | 2023-04-20 | 2023-12-19 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
| KR20250114110A (ko) * | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069809A1 (en) | 2013-11-05 | 2015-05-14 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11234946B2 (en) * | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US9763932B2 (en) * | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10898453B2 (en) * | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US11007189B2 (en) * | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US11273134B2 (en) * | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
-
2021
- 2021-03-29 CN CN202180038675.3A patent/CN115697314A/zh active Pending
- 2021-03-29 EP EP21779322.3A patent/EP4125837A4/en active Pending
- 2021-03-29 KR KR1020227037493A patent/KR20220161414A/ko active Pending
- 2021-03-29 JP JP2022559518A patent/JP7637150B2/ja active Active
- 2021-03-29 CA CA3179048A patent/CA3179048A1/en active Pending
- 2021-03-29 WO PCT/US2021/024718 patent/WO2021202419A1/en not_active Ceased
-
2024
- 2024-12-06 JP JP2024212992A patent/JP7890382B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069809A1 (en) | 2013-11-05 | 2015-05-14 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
Non-Patent Citations (3)
| Title |
|---|
| Axsome News Release, Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder,2019年12月16日,URL: https://axsometherapeuticsinc.gcs-web.com/node/8921/pdf |
| JAMA,2015年,Vol.314, No.12,p.1242-1254,doi:10.1001/jama.2015.10214 |
| O'GORMAN, Cedric et al.,AXS-05 (Dextromethorphan/Bupropion): An Innovative Treatment in Clinical Development for Agitation Associated with Alzheimer's Disease,AAIC CONFERENCE,2018年,P2-033,URL: https://axsometherapeuticsinc.gcs-web.com/static-files/411eadec-47c6-43e1-aa48-f6ad6723345b |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023519965A (ja) | 2023-05-15 |
| CA3179048A1 (en) | 2021-10-07 |
| KR20220161414A (ko) | 2022-12-06 |
| EP4125837A4 (en) | 2024-03-20 |
| WO2021202419A1 (en) | 2021-10-07 |
| CN115697314A (zh) | 2023-02-03 |
| JP2025032232A (ja) | 2025-03-11 |
| EP4125837A1 (en) | 2023-02-08 |
| JP7890382B2 (ja) | 2026-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11419867B2 (en) | Bupropion as a modulator of drug activity | |
| US11571399B2 (en) | Bupropion as a modulator of drug activity | |
| US11524008B2 (en) | Bupropion as a modulator of drug activity | |
| US11497721B2 (en) | Bupropion as a modulator of drug activity | |
| US11617728B2 (en) | Bupropion as a modulator of drug activity | |
| US11596627B2 (en) | Bupropion as a modulator of drug activity | |
| US11433067B2 (en) | Bupropion as a modulator of drug activity | |
| US11285118B2 (en) | Bupropion as a modulator of drug activity | |
| US11382874B2 (en) | Bupropion as a modulator of drug activity | |
| US11510918B2 (en) | Bupropion as a modulator of drug activity | |
| US11534414B2 (en) | Bupropion as a modulator of drug activity | |
| US11617747B2 (en) | Bupropion as a modulator of drug activity | |
| US11571417B2 (en) | Bupropion as a modulator of drug activity | |
| US11439636B1 (en) | Bupropion as a modulator of drug activity | |
| US11357744B2 (en) | Bupropion as a modulator of drug activity | |
| US11191739B2 (en) | Bupropion as a modulator of drug activity | |
| US20250032432A1 (en) | Bupropion as a modulator of drug activity | |
| US11541021B2 (en) | Bupropion as a modulator of drug activity | |
| US10933034B2 (en) | Bupropion as a modulator of drug activity | |
| US11020389B2 (en) | Bupropion as a modulator of drug activity | |
| US10966941B2 (en) | Bupropion as a modulator of drug activity | |
| US20230277478A1 (en) | Bupropion as a modulator of drug activity | |
| US10945973B2 (en) | Bupropion as a modulator of drug activity | |
| US10898453B2 (en) | Bupropion as a modulator of drug activity | |
| JP2025032232A (ja) | アルツハイマー病に関連する焦燥を治療するための医薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221125 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230711 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240502 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250214 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7637150 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |